The Novozymes stock is listed on Nasdaq Copenhagen and included in the OMX Copenhagen CAP 25 index.
Novozymes' common stock consists of two types: A shares and B shares, both with a nominal value of DKK 2 per share. All A stock is held by Novo Holdings A/S, and an A share carries 10 times as many votes as a B share. At the end of 2017, Novo Holdings A/S held 25.5% of the total common stock and, through its holding of the A stock and a proportion of the B stock (24,031,400 shares), controlled 71.2% of the votes. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation, and Novozymes is therefore included in the consolidated financial statements of the Novo Nordisk Foundation.
At year-end, Novozymes had more than 55,000 shareholders, of whom 95% were private shareholders in Denmark. Fifty institutional investors, including Novo Holdings A/S, owned approximately 50% of the B shares. Roughly 70% of the B shares were held outside of Denmark. Novozymes held 4.8% of the
B shares, equivalent to 4% of the total common stock.
Besides Novo Holdings A/S, Baillie Gifford & Co. held more than 5% of Novozymes’ B shares at December 31, 2017.
Novozymes' share price increased by 46% during the year. For comparison, the OMXC20CAP increased by 13% in 2017.
The average daily trading volume of Novozymes' stock in 2017 was 863,035 shares, or DKK 149 million, making it the 11th most actively traded company on Nasdaq Copenhagen, compared with the 10th in 2016. At year-end, the total market cap of Novozymes was DKK 108.1 billion, split between DKK 89.1 billion for the B shares and DKK 19.0 billion for the nontraded A shares, assuming the same value per share as for the B shares.
Over the past five years, Novozymes' stock has generated an average annual return (compounded) to shareholders of 19%. Total shareholder return in 2017 was 47%, adjusted for dividends.